-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AI-061 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AI-061 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AI-061 in Solid Tumor Drug Details: AI-061 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Gotistobart in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Gotistobart in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Gotistobart in Solid Tumor Drug Details: ONC-392 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Gotistobart in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Gotistobart in Metastatic Castration-Resistant Prostate Cancer (mCRPC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Gotistobart in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Gotistobart in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Gotistobart in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Gotistobart in Non-Small Cell Lung Cancer Drug Details: ONC-392...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tozorakimab in Chronic Bronchitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tozorakimab in Chronic Bronchitis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tozorakimab in Chronic Bronchitis Drug Details: Tozorakimab (MEDI-3506) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Diphtheria + Haemophilus Influenzae [serotype B] + Hepatitis B + Pertussis (whole Cell) + Poliomyelitis + Tetanus) (hexavalent) Vaccine in Hepatitis B
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Diphtheria + Haemophilus Influenzae [serotype B] + Hepatitis B + Pertussis (whole Cell) + Poliomyelitis + Tetanus) (hexavalent) Vaccine in Hepatitis B report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Alisertib in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Alisertib in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Alisertib in...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Talazoparib in Metastatic Transitional (Urothelial) Tract Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Talazoparib in Metastatic Transitional (Urothelial) Tract Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Talazoparib in Metastatic Transitional (Urothelial) Tract Cancer Drug...